Advanced Micro Devices, Inc. vs Amgen Inc.: Strategic Comparison

This in-depth comparison examines Advanced Micro Devices, Inc. and Amgen Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Advanced Micro Devices, Inc. on its own, evaluating Amgen Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Advanced Micro Devices, Inc. and Amgen Inc. is widest.

On the headline numbers, Advanced Micro Devices, Inc. reports annual revenue of $34.6B against $36.8B for Amgen Inc., while their respective market capitalizations stand at $999.5B and $228.2B. Both Advanced Micro Devices, Inc. and Amgen Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Advanced Micro Devices, Inc.: Advanced Micro Devices spent most of its first four decades as Intel's smaller x86 rival, competitive in some generations and close to failure in others. It moved its fabs into GlobalFoundries in 2009, and after Lisa Su became CEO in October 2014 it concentrated its engineering budget on one clean-sheet CPU core, Zen. Ryzen and EPYC arrived in 2017, and the Xilinx and Pensando deals in 2022 widened the portfolio past CPUs and graphics. AMD now designs server and desktop processors, Radeon graphics, Instinct AI accelerators, and adaptive SoCs, and supplies the semi-custom chips inside the PlayStation 5 and Xbox Series consoles.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

Advanced Micro Devices, Inc. and Amgen Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Advanced Micro Devices, Inc. and Amgen Inc..

Advanced Micro Devices, Inc. business model: Advanced Micro Devices runs a fabless semiconductor model. It designs CPUs, GPUs, AI accelerators, FPGAs, and adaptive SoCs, and contracts the wafer manufacturing to outside foundries, primarily TSMC. That structure keeps leading-edge fabrication off AMD's balance sheet and makes engineering its largest investment: research and development cost $8.1B in FY2025, about 23% of revenue. Revenue comes from three reportable segments. Data Center, $16.6B in FY2025, covers EPYC server CPUs, Instinct AI accelerators, Pensando DPUs, AI network interface cards, and adaptive SoCs sold to cloud providers, enterprises, and HPC customers. Client and Gaming, $14.6B, covers Ryzen desktop and notebook processors, chipsets, Radeon discrete graphics, and the semi-custom SoCs inside PlayStation and Xbox consoles; within it Client was $10.6B and Gaming $3.9B. Embedded, $3.5B, covers the Xilinx-derived FPGA, system-on-module, and adaptive SoC lines sold into telecom, aerospace, defense, automotive, and industrial equipment. The design lever is chiplets: AMD splits a processor into several smaller dies joined by Infinity Fabric, which raises usable yield and lets it mix process nodes inside one package.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Advanced Micro Devices, Inc. stack up against those of Amgen Inc..

Advanced Micro Devices, Inc. competitive advantage: AMD's advantage is design and packaging execution without fab ownership. Because it buys capacity from TSMC instead of running leading-edge fabs, it can move to a newer process node as soon as the foundry has one in volume. Its chiplet approach assembles a processor from smaller dies linked by Infinity Fabric, which improves usable yield and makes high core-count parts cheaper to build than a single large die. Zen-based EPYC and Ryzen processors converted that into server and client share gains against Intel, and 3D V-Cache gives the Ryzen X3D desktop parts a cache advantage in games.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Future prospects matter as much as current results. The growth strategies below explain how Advanced Micro Devices, Inc. and Amgen Inc. each plan to expand from here.

Advanced Micro Devices, Inc. growth strategy: AMD's growth plan centers on data center AI, funded by $8.1B of research and development in FY2025. It has bought capability rather than waiting to build it: Xilinx in February 2022 for FPGAs and adaptive computing, a deal announced in October 2020 at about $35B in stock and worth roughly $49B at close; Pensando in May 2022 for DPUs at about $1.9B; Silo AI in August 2024 for AI software engineering at about $665M; and ZT Systems in March 2025 for rack-scale systems design. The aim is to sell complete AI racks that combine EPYC CPUs, Instinct accelerators, AI networking, and ROCm software instead of individual chips, while Ryzen and Radeon keep funding the effort.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

A closer look at the financial trajectory of Advanced Micro Devices, Inc. and Amgen Inc. rounds out the comparison.

Advanced Micro Devices, Inc.: AMD's decade is a turnaround with a paper trail. Revenue fell to $4.0B in 2015 and the company lost $660M; its market value ended that year near $2.3B. Zen-based Ryzen and EPYC parts, and Intel's process delays, shifted the mix toward servers and then AI accelerators. FY2025 revenue was $34.6B, up 34% from $25.8B, with net income of $4.3B, a 50% gross margin, $8.1B of research and development spending, and $4.1B of marketing, general and administrative expense. Cash, cash equivalents, and short-term investments rose to $10.6B from $5.1B a year earlier, against $3.3B of total debt principal. The result also absorbed about $440M of net inventory and related charges tied to US export controls on Instinct MI308 products.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.